There seems to be enough celiac disease in women with osteoporosis to justify serologic screening for the GI ailment in all women with osteoporosis, according to the results of a large screening trial (3.4 vs. 0.2%).
There seems to be enough celiac disease in women with osteoporosis to justify serologic screening for the GI ailment in all women with osteoporosis, according to the results of a large screening trial (3.4 vs. 0.2%). Researchers performed serologic screening for celiac disease in 266 women with osteoporosis and 574 without the bone-thinning disease. Those with positive serologic test results for IgA antitissue transglutaminase (anti-TTG) or IgA antiendomysial antibody were offered endoscopic intestinal biopsy.
Nine osteoporotic women and one nonosteoporotic woman had positive biopsy results. The researchers found that the more severe the celiac disease, the more severe the osteoporosis. More importantly, treating patients found to be positive for celiac disease with a gluten-free diet resulted in marked improvement in bone mineral density.
The authors of the study concluded that at an approximate cost of $45 for anti-TTG testing and a prevalence rate of celiac disease among osteoporotic women of 3.4%, identifying a patient with celiac disease via serologic screening would cost about $1,500.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More